GeoVax Aims to Break Monopoly in Global Mpox and Smallpox Vaccine Market with GEO-MVA Candidate

The global market for vaccines targeting mpox and smallpox has become a procurement-driven sector with recurring demand, supported by national stockpile programs across the United States, Europe, and allied countries, ongoing purchasing by global health organizations, and outbreak-driven surge demand tied to periodic transmission events. Recent mpox outbreaks across multiple continents, including the emergence of more virulent strains, have reinforced the need for sustained vaccine supply beyond emergency response cycles. The current global supply of Modified Vaccinia Ankara (MVA) vaccines, the preferred option due to their safety for vulnerable populations, is concentrated with a single commercial supplier, creating a market structure with limited surge capacity during outbreaks, repeated depletion of government stockpiles, and increased focus on supply chain resilience.

Governments and public health agencies are increasingly prioritizing the establishment of additional sources of MVA vaccine supply, expansion of domestic and allied manufacturing capacity, and reduced dependence on single-source providers for critical countermeasures. Public disclosures and procurement activity indicate this market has generated hundreds of millions of dollars in annual procurement in recent years, includes multiyear purchasing frameworks and forward-looking supply agreements, and is supported by both baseline stockpiling demand and outbreak-driven purchasing cycles. GeoVax believes these dynamics support a durable and expanding global market rather than a one-time, pandemic-driven opportunity.

GeoVax’s GEO-MVA vaccine candidate is being developed to address the current supply-demand imbalance, positioned as a potential second-source MVA vaccine with key attributes including leveraging the established MVA platform, a defined regulatory pathway based on immuno-bridging to an approved MVA vaccine, and late-stage development readiness with Phase 3 initiation planned during 2026. The company believes GEO-MVA has the potential to support national stockpile replenishment programs, global outbreak response efforts, and long-term preparedness and biodefense strategies. The mpox/smallpox vaccine market is increasingly shaped by the intersection of public health preparedness, driven by recurring mpox outbreaks and evolving viral threats, and national security and biodefense priorities, including protection against biological threats.

Recent U.S. and international policy initiatives have emphasized strengthening biosecurity infrastructure, expanding domestic manufacturing capabilities, and ensuring reliable access to critical medical countermeasures. GeoVax believes GEO-MVA is positioned for both civilian and biodefense procurement channels, with its planned development timeline synchronized with anticipated stockpile replenishment cycles following recent depletion, continued global procurement activity driven by outbreak preparedness, and increasing policy emphasis on supply diversification initiatives. David Dodd, Chairman and Chief Executive Officer of GeoVax, stated that the market is an active, procurement-driven one with recurring demand and increasing strategic importance, currently defined by supply concentration and limited surge capacity.

He added that if approved, GEO-MVA, which is expected to begin a pivotal Phase 3 trial this year, is positioned to enter this market as a second-source MVA vaccine when governments and global health organizations are actively seeking to diversify supply and strengthen preparedness. The company’s focus is on executing the next phase of development and aligning GEO-MVA with procurement frameworks that support both long-term stockpiling and rapid response capabilities. For more information about the company’s broader pipeline and intellectual property, visit https://www.geovax.com. The original release can be viewed on https://www.newmediawire.com.